跳至主要内容
临床试验/NCT00758251
NCT00758251已完成不适用

Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

AstraZeneca2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2008年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
80
试验地点
2
主要终点
Improvement in CGI scores and BPRS comparing visits 1 and 3.

研究概览

简要总结

The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
  • Signed and dated Patient Informed Consent (ICF)

排除标准

  • Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

结局指标

主要结局

Improvement in CGI scores and BPRS comparing visits 1 and 3.

时间窗: twice with 4 week interval

次要结局

  • To evaluate compliance to therapy(twice with 4 week interval)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

Observation of Change in Clinical Global Impression... | 临床试验